<code id='2AFA3500C2'></code><style id='2AFA3500C2'></style>
    • <acronym id='2AFA3500C2'></acronym>
      <center id='2AFA3500C2'><center id='2AFA3500C2'><tfoot id='2AFA3500C2'></tfoot></center><abbr id='2AFA3500C2'><dir id='2AFA3500C2'><tfoot id='2AFA3500C2'></tfoot><noframes id='2AFA3500C2'>

    • <optgroup id='2AFA3500C2'><strike id='2AFA3500C2'><sup id='2AFA3500C2'></sup></strike><code id='2AFA3500C2'></code></optgroup>
        1. <b id='2AFA3500C2'><label id='2AFA3500C2'><select id='2AFA3500C2'><dt id='2AFA3500C2'><span id='2AFA3500C2'></span></dt></select></label></b><u id='2AFA3500C2'></u>
          <i id='2AFA3500C2'><strike id='2AFA3500C2'><tt id='2AFA3500C2'><pre id='2AFA3500C2'></pre></tt></strike></i>

          knowledge

          knowledge

          author:fashion    Page View:78
          Sammy Kimball for STAT

          Can unicorns survive without data? Did biotech get over its skis? And what is going on at Biogen?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Allison DeAngelis joins us to share her reporting on how the handsomely funded Laronde Therapeutics, billed as “Moderna 2.0,” ran into behind-the-scenes problems with its scientific data. We also discuss how Biogen’s boardroom scandal has roiled a company that was supposed to be entering a new era.

          advertisement

          For more on what we cover, here’s the Laronde story; here’s the latest on Biogen; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          focus

          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more
          FDA approves Eli Lilly ulcerative colitis treatment Omvoh
          FDA approves Eli Lilly ulcerative colitis treatment Omvoh

          DarronCummings/APTheFoodandDrugAdministrationonThursdayapprovedanEliLillydrugthattakesanewapproachto

          read more
          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more

          Readout Newsletter: The latest on Moderna, Apellis, and Merck

          JakubPorzycki/NurPhotoviaAPWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetou